Globus Medical, Inc.

NYSE:GMED

Medical - Devices

Healthcare
$70.53 -2.71%

-$2.10 today

Market cap
$9.34B
Beta
0.95
P/E (TTM)
17.4
EPS (TTM)
$4.33
52W Low $51.79High $101.40

Volume 1.43M

Average 1.45M

GMED Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Globus Medical, Inc.NYSE: GMED

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow growth accelerates

Q2 FY2026 free cash flow of $176.57M rose 571.3% year over year, ahead of the +45.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +78.0% a year.

Context

  • Free cash flow amounted to 20.0% of revenue in FY2025, up 3.9 pp from a year earlier.
  • Free cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +571.3% holds above the trailing-twelve-month pace of +45.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$176.57M+8.5% QoQ
Last fiscal yearDec 2025
$588.77M+45.3% YoY
LTMJun 2026
$750.59M+45.1% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+571.3%——
1 year+45.3%——
3-year CAGR+78.0%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
588.77M USD
Year-over-year change
+45.3%
4-year CAGR
+28.0%

Free Cash Flow vs competitors

How GMED compares with its peers on the latest reported figures

  • GMED's LTM Jun 2026 free cash flow of $750.59M is the 4th largest of the 10 companies compared; the peer median is $7.77M.
  • Its year-over-year change of +45.1% is the 4th highest of 10, against a peer median of +28.5%.
  • Free cash flow amounts to 23.9% of revenue for GMED, versus a peer median of 6.4%.
GMED Competitors Peer median
Free Cash Flow for GMED and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$4.7B +16.8%+28.1%18.2%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$1.83B +28.5%+11.3%21.5%
SNNSmith & Nephew plcFY2025$852M +40.6%+97.9%13.8%
GMEDGlobus Medical, Inc.LTM Jun 2026$750.59M +45.1%+78.0%23.9%
BVSBioventus Inc.LTM Mar 2026$100.63M +320.5%—17.5%
KIDSOrthoPediatrics Corp.LTM Mar 2026$12.63M -65.8%-20.5%5.2%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$7.77M +182.7%—6.4%
ATECAlphatec Holdings, Inc.LTM Mar 2026$6.95M +108.6%—0.9%
SIBNSI-BONE, Inc.LTM Mar 2026$5.55M -72.6%-43.8%2.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$3.63M -24.4%-66.7%0.4%
Peer median (excluding GMED) $7.77M+28.5%-4.6%6.4%

Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income149.19M190.17M122.87M102.98M537.87M
Depreciation & Amortization69.87M68.25M144.73M254.02M276.84M
Deferred Income Tax(17.62M)(22.22M)(57.79M)(125.9M)18.63M
Stock-Based Compensation30.59M32.81M52.74M54.19M49.78M
Change in Working Capital(17.25M)(105.26M)(116.6M)(97.55M)(82.71M)
Accounts Receivables(25.9M)(50.84M)(49.91M)(78.06M)(52.18M)
Inventory(11.97M)(61.75M)(70.33M)(29.86M)(17.6M)
Accounts Payables3.68M14.42M(14.22M)17.66M8.49M
Other Working Capital16.93M(7.09M)17.87M(7.3M)(21.42M)
Other Non-Cash Items61.5M14.72M97.54M332.9M(46.96M)
Operating Cash Flow276.27M178.47M243.5M520.64M753.45M
Capital Expenditures(56.9M)(74.05M)(78.27M)(115.43M)(164.68M)
Acquisitions (Net)(34.49M)(31.44M)(296.03M)(17.64M)13.46M
Purchases of Investments(622.36M)(419.53M)(100.64M)(113.5M)(107.53M)
Sales of Investments337.81M414.65M777.91M70.52M179.49M
Other Investing Activities0000(275.75M)
Investing Cash Flow(375.94M)(110.36M)302.97M(176.05M)(355.01M)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0(144.49M)(225.56M)(85.79M)(300.45M)
Dividends Paid00000
Other Financing Activities54.15M34.53M(6.26M)58.09M(378.71M)
Financing Cash Flow54.15M(109.96M)(231.82M)(27.7M)(679.16M)
Effect of Forex Changes(810K)(747K)2.18M255K22.45M
Net Change in Cash(46.33M)(42.6M)316.83M317.15M(258.28M)
Free Cash Flow219.38M104.42M165.23M405.21M588.77M

Globus Medical, Inc.

NYSE:GMED

Intrinsic Alpha fair value

Locked

Current Price

$70.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.